Haoyun Technologies (300448.SZ): The actual controller intends to transfer 5% of the company's shares by agreement.
Haoyun Technologies (300448.SZ) announced that Mao Qingjiang, the company's controlling shareholder and actual controller, signed a Share Transfer Agreement on October 18, 2026, intending to transfer 33.83 million shares of the company held by him (accounting for 5% of the company's total share capital and 5.07% of the company's total share capital after deducting shares in the repurchase special account) to Shenzhen Lingfeng Private Securities Fund Management Co., Ltd. (on behalf of "Lingfeng Chenhai Zhitou Private Securities Investment Fund") (referred to as "Lingfeng Fund") by way of agreement transfer.
Haoyun Technologies (300448.SZ) announced that Mao Qingjiang, the company's controlling shareholder and actual controller, signed a Share Transfer Agreement on October 18, 2026, intending to transfer 33.83 million shares of the company held by him (accounting for 5% of the company's total share capital and 5.07% of the company's total share capital after deducting shares in the repurchase special account) to Shenzhen Lingfeng Private Securities Fund Management Co., Ltd. (on behalf of "Lingfeng Chenhai Zhitou Private Securities Investment Fund") (referred to as "Lingfeng Fund") by way of agreement transfer. The total transfer price of the subject shares is RMB 179 million. After the transfer is completed, Lingfeng Fund will hold 33.83 million shares of the company and become a shareholder holding 5% (inclusive) or more of the company. This transaction will not result in a change in the company's controlling shareholder or actual controller.
Related Articles

Chengdu Olymvax Biopharmaceuticals Inc(688319.SH) received the Phase III clinical study summary report for the recombinant Staphylococcus aureus vaccine (E. coli)

US Stock Market Move | Amazon.com, Inc. (AMZN.US) rose nearly 4%; Morgan Stanley named it a top pick and raised its price target to $350.

AI agent adoption may be constrained by compute bottlenecks; Morgan Stanley remains bullish on Meta's (META.US) long-term commercialization prospects, raises target price to $820 and maintains "Overweight" rating.
Chengdu Olymvax Biopharmaceuticals Inc(688319.SH) received the Phase III clinical study summary report for the recombinant Staphylococcus aureus vaccine (E. coli)

US Stock Market Move | Amazon.com, Inc. (AMZN.US) rose nearly 4%; Morgan Stanley named it a top pick and raised its price target to $350.

AI agent adoption may be constrained by compute bottlenecks; Morgan Stanley remains bullish on Meta's (META.US) long-term commercialization prospects, raises target price to $820 and maintains "Overweight" rating.






